N-(2-(2-methyl-1H-indol-1-yl)ethyl)-4-(piperidin-4-yloxy)benzamide | 1616961-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(2-(2-methyl-1H-indol-1-yl)ethyl)-4-(piperidin-4-yloxy)benzamide
• 英文别名: N-[2-(2-methylindol-1-yl)ethyl]-4-piperidin-4-yloxybenzamide
• CAS: 1616961-03-5
• 化学式: C₂₃H₂₇N₃O₂
• 分子量: 377.486
• InChiKey: LPNCXNOUMIUGPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  55.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(Piperidin-4-yloxy)-benzoic acid 、 [2-(2-甲基-1H-吲哚-1-基)乙基]胺 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 N-(2-(2-methyl-1H-indol-1-yl)ethyl)-4-(piperidin-4-yloxy)benzamide
  参考文献：
  名称：

  Development of second generation EP2 antagonists with high selectivity

  摘要：

  EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.05.076

文献信息

• Development of second generation EP2 antagonists with high selectivity
  作者：Thota Ganesh、Jianxiong Jiang、Ray Dingledine

  DOI：10.1016/j.ejmech.2014.05.076

  日期：2014.7

  EP2 receptor has emerged as an important biological target for therapeutic intervention. In particular, it has been shown to exacerbate disease progression of a variety of CNS and peripheral diseases. Deletion of the EP2 receptor in mouse models recapitulates several features of the COX-2 inhibition, thus presenting a new avenue for anti-inflammatory therapy which could bypass some of the adverse side effects observed by the COX-2 inhibition therapy. We have recently reported a cinnamic amide class of EP2 antagonists with high potency, but these compounds exhibited a moderate selectivity against prostanoid receptor DP1. Moreover they possess acrylamide moiety in the structure, which may result in liver toxicity over longer period of use in a chronic disease model. Thus, we now developed a second generation compounds that devoid of the acrylamide functionality and possess high potency and improved (>1000-fold) selectivity to EP2 over other prostanoid receptors. (C) 2014 Elsevier Masson SAS. All rights reserved.